Expanding the Redox Biology Toolbox
Expanding the Redox Biology Toolbox
批准号:
10009815
负责人:
Xiaoli Qi
金额:
$15.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-07-01 至 2023-06-30
关键词:
AffectBasic ScienceBiological AssayBiological ProcessBiologyCarboxylic AcidsCell NucleusCellsChargeChemistryClinicalClinical ResearchComputer softwareDevelopmentDivision of Cancer Treatment and DiagnosisDockingDrug ScreeningElectrostaticsEndoplasmic ReticulumEquilibriumEukaryotic CellGenerationsGlutathioneGoalsHalf-LifeHomeostasisHybridsHydrophobicityLaboratory DiagnosisLeadLegal patentLengthLigandsLysosomesMitochondriaMonitorNational Cancer InstituteOrganellesOxidation-ReductionPatientsPerformancePharmaceutical ChemistryPharmaceutical PreparationsPhaseProteinsProtocols documentationQuality ControlReactionReportingSamplingSpecificitySulfhydryl CompoundsTimeTissuesTransfectionTransferasebasecommercializationfunctional groupimprovedinterestradioresistantreaction ratereal time monitoringsmall moleculetooltumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Glutathione (GSH) is the most abundant non-protein thiol in eukaryotic cells. GSH maintains cellular redox
homeostasis and is involved in numerous biological processes. These important functions are dynamically
regulated by the intracellular concentration and distribution of GSH. Currently, the concentration of intracellular
GSH is derived from either cell lysates or GSH-S-transferase (GST) dependent probes. These approaches,
however, cannot provide information about the real-time dynamics of GSH concentration changes. We reported
the first reversible reaction-based GSH probe (ThiolQuant Green) that can perform single-point quantification of
GSH levels in living cells and developed the 2nd generation GSH probe—RealThiol (RT)—that allows real-time
monitoring of GSH dynamics in living cells. We filed a patent on these GSH probes (WO2016025382) and have
shared the RealThiol probe with >70 redox biology labs around the world. Additionally, the Division of Cancer
Treatment & Diagnosis Laboratory Support at National Cancer Institute (NCI) is interested in applying our GSH
probes in their drug screening assays and requested gram quantity of RT probes. The overarching goal for this
Phase I project is to develop probes that can monitor the dynamics of the concentration change of GSH in real-
time with subcellular specificity and to provide a complete toolset to study GSH-related redox biology. For Phase
II commercialization, we will focus on both basic and clinical research. We will develop assay kits for GSH-related
biology, such as ferroptosis. We will also apply our GSH probes in clinical samples to help identify patients with
drug/radiation-resistant tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金